MEMPHASYS LTD Total Assets
MEMPHASYS LTD total assets. Based on the latest financial reports, MEMPHASYS LTD (IG7) holds total assets worth €12.43 Million EUR (≈ $14.53 Million USD) as of June 2024. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see MEMPHASYS LTD (IG7) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of MEMPHASYS LTD (2021–2024)
Total assets of MEMPHASYS LTD from 2021 to 2024. This chart illustrates how MEMPHASYS LTD's total assets have evolved over time, based on quarterly financial data. See latest MEMPHASYS LTD stock price today for real-time trading data and today's change.
MEMPHASYS LTD - Asset Composition Analysis
MEMPHASYS LTD Total Assets Breakdown (June 2024)
MEMPHASYS LTD total assets breakdown as of June 2024. MEMPHASYS LTD's total assets of €12.43 Million consist of 13.0% current assets and 87.0% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 2.2% |
| Accounts Receivable | €0.00 | 0.0% |
| Inventory | €164.76K | 1.3% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €10.09 Million | 81.2% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how MEMPHASYS LTD's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore IG7 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: MEMPHASYS LTD's current assets represent 13.0% of total assets in 2024, a decrease from 26.9% in 2021.
- Cash Position: Cash and equivalents constituted 2.2% of total assets in 2024, down from 14.6% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 81.0% of total assets, an increase from 60.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 81.2% of total assets.
MEMPHASYS LTD Competitors by Total Assets
Key competitors of MEMPHASYS LTD based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
GN Store Nord
CO:GN
|
Denmark | Dkr29.23 Billion |
|
Shanghai Aohua Photoelectricity Endoscope Co. Ltd. A
SHG:688212
|
China | CN¥1.86 Billion |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
L&C Bio Co. Ltd
KQ:290650
|
Korea | ₩497.94 Billion |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
Germany | €13.91 Million |
|
Affluent Medical SAS
PA:AFME
|
France | €59.84 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩131.65 Billion |
MEMPHASYS LTD - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.31 | - | - |
| Quick Ratio | 0.28 | - | - |
| Cash Ratio | 0.00 | - | - |
| Working Capital | €-3.64 Million | - | - |
MEMPHASYS LTD - Advanced Valuation Insights
This section examines the relationship between MEMPHASYS LTD's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.36 |
| Latest Market Cap to Assets Ratio | 0.29 |
| Asset Growth Rate (YoY) | -15.3% |
| Total Assets | €12.43 Million |
| Market Capitalization | $3.61 Million USD |
Valuation Analysis
Below Book Valuation: The market values MEMPHASYS LTD's assets below their book value (0.29x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: MEMPHASYS LTD's assets decreased by 15.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for MEMPHASYS LTD (2021–2024)
The table below shows the annual total assets of MEMPHASYS LTD from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-06-30 | €12.43 Million ≈ $14.53 Million |
-15.26% |
| 2023-06-30 | €14.67 Million ≈ $17.15 Million |
+3.87% |
| 2022-06-30 | €14.12 Million ≈ $16.51 Million |
+2.80% |
| 2021-06-30 | €13.74 Million ≈ $16.06 Million |
-- |
About MEMPHASYS LTD
Memphasys Limited develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. The company offers Felix system, a device separates sperm from raw semen by electrophoresis process and size exclusion membranes. It also provides RoXsta, an in-vitro diagnostic device; and AI-Port, an ambie… Read more